share_log

Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference

Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference

jaguar health 将于12月3日在NobleCon20上演讲,并于12月5日在Emerging Growth Conference上演讲
Jaguar Health ·  11/24 23:00

SAN FRANCISCO, CA / ACCESSWIRE / November 25, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on December 3, 2024 at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference, and present virtually on December 5, 2024 at the Emerging Growth Conference.

SAN FRANCISCO, CA / ACCESSWIRE / 2024年11月25日 / jaguar health公司 (纳斯达克:JAGX) 今日宣布,公司创始人、总裁兼首席执行官Lisa Conte将于2024年12月3日亲自参加Noble Capital Markets第20届新兴成长股权会议,并于2024年12月5日通过网络虚拟参加新兴成长会议。

Participation Instructions for Jaguar Health's In-Person Presentation at NobleCon20
When: Tuesday, December 3, 2024 at 10:30 - 10:55 AM Eastern Standard Time
Where: Presentation Room 3, Florida Atlantic University, Executive Education Complex, Boca Raton, Florida
Registration link for conference: Click Here
Replay: A video webcast of the presentation will be available the following day as part of a complete catalog of presentations available at and on Noble's Channelchek investor portal: . The webcast will be archived on the NobleCon website and on Channelchek.com for 90 days following the event.

jaguar health公司在NobleCon20现场演示的参与指南
时间:2024年12月3日 周二 上午10:30 - 10:55 美国东部标准时间
地点:佛罗里达大西洋大学,行政教育综合楼,博卡拉顿,佛罗里达,演讲厅3
会议注册链接:点击这里
重播:演示的视频网络直播将于次日提供,作为Noble的Channelchek投资者门户网站上所有演示的完整目录的一部分。 网络直播将被存档在NobleCon网站和Channelchek.com上,活动结束后的90天内。

Participation Instructions for Jaguar Health's Virtual Presentation at the Emerging Growth Conference
When: Thursday, December 5, 2024 from 10:50 - 11:20 AM Eastern Standard Time
Where: Online (Click Here)
Registration link for conference: Click Here
Replay: An archived webcast of the presentation will be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel.

jaguar health公司在新兴成长会议上的虚拟演示参与指南
时间:2024年12月5日 周四 上午10:50 - 11:20 美国东部标准时间
地点:在线(点击这里)
会议注册链接:点击这里
重播:演示的存档网络广播将在EmergingGrowth.com和Emerging Growth YouTube频道上提供。

About the Jaguar Health Family of Companies

关于Jaguar Health公司家族

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

Jaguar Health, Inc.(Jaguar)是一家商业化阶段的制药公司,专注于开发可持续从雨林地区的植物中提取的新型专有处方药,用于治疗与过度肠道功能相关的人和动物胃肠不适,包括慢性致残腹泻,尿急,肠失禁和痉挛性疼痛等症状。Jaguar旗下的Napo Pharmaceuticals(Napo)专注于为多个复杂的疾病治疗的需要提供人用处方药的开发和商业化。市场上,Crofelemer通过Mytesi品牌名由FDA批准用于缓解HIV/AIDS患者在抗逆转录病毒治疗下的艾滋病相关性腹泻症状。Jaguar旗下的Napo Therapeutics是一家成立于2021年,总部位于意大利米兰的意大利公司,专注于扩大Crofelemer在欧洲和特定孤儿和/或罕见疾病中的应用。Jaguar Animal Health是Jaguar的商标名称。Magdalena Biosciences是Jaguar和Filament Health Corp.组成的合资公司,从Jaguar的灵性治疗倡议(ETI)中出现,致力于开发来自植物的新型处方药用于治疗精神健康问题。

For more information about:

更多信息:

Jaguar Health, visit
Napo Pharmaceuticals, visit
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

请访问jaguar health。
访问Napo Pharmaceuticals
请访问napotherapeutics.com。
请访问magdalenabiosciences.com。
访问Bluesky的Make Cancer Less Shitty患者倡导计划,以及X、Facebook和Instagram

Forward-Looking Statements

前瞻性声明

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will present at NobleCon20 and at the December 2024 Emerging Growth Conference. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

本新闻稿中的某些声明构成“前瞻性声明”。其中包括关于jaguar health预计jaguar管理层将在NobleCon20和2024年12月新兴成长大会上发表演讲的声明。在某些情况下,您可以通过诸如“可能”、“将”、“应该”、“期待”、“计划”、“旨在”、“预期”、“可能”、“打算”、“目标”、“项目”、“考虑”、“相信”、“估计”、“预测”、“潜在”或“继续”等术语辨识前瞻性 语句。本新闻稿中的前瞻性声明仅为预测。jaguar health在很大程度上基于其对未来事件的当前期望和展望作出这些前瞻性声明。这些前瞻性声明仅适用于本公告日,并且受到多个风险、不确定性和某些无法预测或量化以及超出jaguar health 控制范围的假设的影响。除非适用法律要求,jaguar health不打算公开更新或修订本公告中包含的任何前瞻性声明,无论是出于任何新信息、未来事件、变化情况或其他原因。

Contact:

联系方式:

hello@jaguar.health

hello@jaguar.health

Jaguar-JAGX

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

资料来源:Jaguar Health, Inc。


press releaseaccesswire.com
新闻稿 accesswire.com

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发